"We will make every diabetic patient in China have his own blood sugar meter." With this dream in mind, Sannuo Bio was founded in 2002, embarking on the journey of promoting economical and affordable blood sugar monitoring products in China and developing the local diabetes health industry. Adhering to the core values ​​of "No for Love", Sannuo Bio has always been committed to innovation in biosensing technology, developing, producing and selling a series of rapid diagnostic and testing products for patients with chronic diseases and medical and health professionals.

Since its establishment, Sanno blood glucose meter, characterized by "accuracy, simplicity and economical", has received unanimous praise from Chinese consumers. In China, more than 50% of diabetic patients use Sannuo's products. The company can proudly claim that the company has successfully promoted the popularization of blood glucose meters in China and the self-glycemic management results of Chinese diabetic patients.

However, giving diabetics a blood glucose meter is only the company's first step. In order to achieve the goal of effectively controlling blood sugar levels, diabetic patients need to systematically learn related knowledge such as blood sugar monitoring, diet, and exercise. Therefore, the company is actively expanding into the field of diabetes medical services, creating a "hardware + software + service" model to help diabetic patients understand and master comprehensive diabetes management, and move towards the goal of "from promoter of blood glucose meters to diabetes digital management experts" .

This goal inspired every Sannuo employee. From this, the company provided a more advanced blood sugar monitoring system, developed a multi-analyte analyzer to provide more diabetes-related information, and launched a hospital diabetes management platform. , create a closed loop between doctors, patients, nutritionists and diabetes educators. In September 2014, they all acquired Beijing Sannuojianheng Diabetes Hospital and launched a pilot program in the field of diabetes medical services; in January 2016, they participated in the acquisition of Trividia Health Inc, the United States, taking the first step of internationalization, and entering the The frontier of the global blood glucose meter industry; in July 2016, it acquired Polymer Technology Systems, Inc., a joint venture with external strategic investors, actively expanding its POCT detection business and providing a more comprehensive overall solution for chronic disease prevention and control.

Ultimately, the company will form an ecosystem of diabetes management, providing a systematic solution to improve the quality of life of diabetic patients, reduce the communication costs between health care providers and patients, and improve the social health care economy.